程序性细胞凋亡因子4（PDCD4）和Ki67蛋白在蕈样肉芽肿中的表达
|
摘要
研究背景:
蕈样肉芽肿(Mycosis Fungoides,MF)是原发于皮肤的亲表皮性皮肤T细胞淋巴瘤(cutaneous T cell lymphoma,CTCL),系一种最常见的低度恶性皮肤非霍奇金淋巴瘤。其早期局限于皮肤,随着病情的缓慢发展,晚期可侵犯淋巴结及内脏系统。MF的发病机制目前仍不清楚,讫今无满意的治疗方法。免疫学异常与其发病密切相关,表现为患者皮损中树突状细胞分布和功能异常,T细胞凋亡障碍,Fas表达下降和FasL表达增加,趋化因子及其受体、IL-4、IL-15、CTLA-4、HECA-452等免疫分子异常表达。其中T细胞的凋亡障碍导致肿瘤细胞的凋亡减少,从而促进MF的发展。
亲表皮现象是MF组织病理学的特征之一,这提示表皮细胞与淋巴细胞的相互作用可能在MF的发病中发挥一定作用。角质形成细胞(keratinocyte,KC)是人体表皮中的主要细胞,具有一定的抗原递呈作用,主动参与皮损中T细胞的再活化。同时其分泌的细胞因子在皮肤免疫系统中也发挥重要作用,MF时角质形成细胞中某些免疫分子的表达存在着显著不同,如IL-15蛋白的高度表达是皮肤T细胞淋巴瘤的一个特征。
PDCD4是一种抑癌基因,PDCD4蛋白是细胞凋亡所需要的新生的大分子复合物之一。其通过抑制肿瘤细胞的转录和翻译过程中起始复合物的形成抑制肿瘤细胞的生长。多种肿瘤细胞中PDCD4蛋白表达降低甚至缺失,并且随着肿瘤恶性程度的递增以及患者生存时间的减少,PDCD4的表达发生丢失情况也不断加重,证明PDCD4参与了多种肿瘤的发生和发展,在抑制肿瘤的形成中发挥了重要作用。目前已有PDCD4缺陷鼠自然发生淋巴瘤并且寿命显著缩短的报道,而且大多数肿瘤来源于B细胞,并不断转移到肝和肾。证明PDCD4在网状内皮系统肿瘤中也发挥了一定作用。关于皮肤T细胞淋巴瘤中该因子的表达及其影响的研究少见报道,表皮细胞在MF发病中的作用研究也较少。
Ki67抗原简称Ki67,是一种细胞核抗原,仅在增殖细胞核中表达,其单克隆抗体能标记G_1后期、S期、G_2期和M期细胞核,而G_0期和G_1早期细胞核不被标记。Ki67是目前应用最广泛的增殖细胞指标之一,是较为敏感的细胞增生分化指标。Ki67的测定是评估人类各种组织增殖组分可靠且简单的方法。
为此我们检测了PDCD4和Ki67蛋白在不同期蕈样肉芽肿的表皮及真皮中的表达,以正常皮肤为正常对照,以扁平苔藓为炎症对照,探讨PDCD4在MF发病中的作用,进而初步了解角质形成细胞在MF发病及病情进展中的作用。
目的:
检测并比较程序性细胞凋亡因子(PDCD4)、Ki67蛋白在正常皮肤、蕈样肉芽肿(MF)及扁平苔藓皮损中的表达,探讨程序性细胞凋亡因子在正常皮肤组织、炎症性皮肤病、不同期蕈样肉芽肿中的表达差异及临床意义,并比较两蛋白的相关性。
材料和方法:
1.收集齐鲁医院皮肤科近10年保存的经临床及病理确诊的27例MF完整蜡块,其中红斑/斑块期MF21例,肿瘤期MF6例;取门诊手术室及整形美容外科切除正常皮肤5例进行甲醛固定与石蜡包埋,作为正常对照组;另取皮肤科病理室保存的扁平苔藓石蜡标本5例,作为炎症对照组。
2.采用免疫组化方法检测并比较PDCD4及Ki67在不同期MF、LP及正常对照组中的表达情况。
3.应用JMT JFX简明统计分析软件10.34进行处理,统计方法采用成组设计多样本比较的秩和检验或方差分析;两蛋白的相关性用Spearman'S等级相关检验进行分析,P＜0.05为差异有统计学意义。
结果:
1.PDCD4在各组皮损中免疫组化染色位置及着色强度结果:
·5例正常对照组的表皮细胞和真皮浸润的淋巴细胞中PDCD4染色均为强阳性,多数为棕褐色,细胞核着色;
·5例扁平苔藓炎症对照组的表皮细胞和真皮浸润的淋巴细胞呈弥漫阳性,棕黄色,分布较密集,胞核染色;
·21例红斑/斑块期MF的表皮阳性细胞数量较正常对照组和扁平苔藓组略减少,胞核、胞浆均有阳性染色,为棕黄色或棕褐色;真皮中阳性细胞较前正常对照组和扁平苔藓组明显减少,胞核、胞浆染色,为棕黄色或淡黄色;
·6例肿瘤期MF表皮及真皮中阳性细胞均明显减少,散在分布,胞核或胞浆染色,部分真皮中PDCD4表达缺失。
·移入表皮的淋巴细胞不染色,真皮浅层距离表皮较近的淋巴细胞染色较淡或不染色。
2.各组PDCD4表达阳性等级的比较结果:
(1)表皮中:
①正常对照组、红斑/斑块期MF组到肿瘤期MF组,PDCD4表达从强阳性到阴性,呈梯度式减弱。红斑/斑块期MF组与正常对照组比较,差异无统计学意义(P＞0.05),其余各组比较,差异有统计学意义(P＜0.05);
②扁平苔藓组、红斑/斑块期MF组到肿瘤期MF组,PDCD4表达从强阳性到阴性,呈梯度式减弱。其中,红斑/斑块期MF组与扁平苔藓组比较,差异无统计学意义(P＞0.05),肿瘤期MF组与扁平苔藓组比较,差异有统计学意义(P＜0.05)。
(2)真皮中:
①正常对照组、红斑/斑块期MF组到肿瘤期MF组,PDCD4表达从强阳性到阴性,呈梯度式减弱。各组间差异均有统计学意义(P＜0.05);
②扁平苔藓组、红斑/斑块期MF组到肿瘤期MF组,PDCD4表达从强阳性到阴性,呈梯度式减弱。其中,红斑/斑块期MF组与扁平苔藓组相比较,差异无统计学意义(P＞0.05),肿瘤期MF组与扁平苔藓组比较差异有统计学意义(P＜0.05)。
3.Ki67蛋白在各组皮损中免疫组化染色位置及着色强度:均为细胞核染色
·5例正常对照组皮肤部分基底细胞阳性表达,棕黄色;真皮中阴性表达;
·5例扁平苔藓组表皮中基底层阳性细胞不连续性分布,基底细胞液化变性处表达减少,其余部分表达稍增多,均以基底层及其上细胞为主;真皮中阳性细胞较多,呈棕褐色或棕黄色,分布密集;
·红斑/斑块期MF组基底层细胞阳性减少,表皮内稍增多,棕黄色;真皮中阳性细胞分布稀疏,棕黄色;
·肿瘤期MF表皮阳性细胞增多不明显,棕褐色;真皮中阳性细胞分布较密集,细胞核大、异型者染色深。
4.各组Ki67表达的阳性细胞数量比较结果:
(1)表皮中:各组比较差异均无统计学意义;
(2)真皮中:
①正常对照组、红斑/斑块期MF组到肿瘤期MF组,Ki67的表达从阴性至强阳性,呈梯度式增强。各组间比较差异均有统计学意义(P＜0.05);
②扁平苔藓组分别与红斑/斑块期MF组和肿瘤期MF组比较差异均无统计学意义(P＞0.05),
5.PDCD4蛋白和Ki67蛋白的相关性分析:红斑/斑块期MF表皮中及真皮中PDCD4蛋白与Ki67蛋白的表达均无相关性(P＞0.05);肿瘤期MF表皮及真皮中PDCD4蛋白与Ki67蛋白的表达均无相关性(P＞0.05)。
结论:
1、随着MF病期的进展,表皮角质形成细胞PDCD4的表达明显下调甚至缺如,提示角质形成细胞在MF的发病及病程进展中可能发挥了重要作用,具体作用尚需进一步研究。
2、真皮中浸润淋巴细胞随着MF病期进展,PDCD4的表达明显下调甚至缺如,提示PDCD4与皮肤淋巴瘤MF的发生及病程进展密切相关,上调PDCD4的表达可能有助于抑制淋巴细胞的过度增殖,PDCD4有望成为皮肤T细胞淋巴瘤治疗的新靶点
3、Ki67在正常皮肤、红斑/斑块期MF及肿瘤期MF真皮中的表达梯度上升,表明Ki67抗原与真皮淋巴细胞的增殖有关,但与扁平苔藓组相比差异并无显著性,提示单一Ki67抗原并不能作为判断细胞恶性增殖的指标。
4、本实验的相关性研究并未发现各期MF皮损中PDCD4的表达与Ki67存在明显的相关性,提示与PDCD4相关的凋亡障碍与细胞的增殖不一定有直接联系。
Objective
To explore the expression of the Programmed Cell Death 4 and Ki67 antigen in the skin infiltrates of normal skin,skin lesions with mycosis fungoide (MF) in different stages and lichen planus(LP);And to explore the significance of the human programmed cell death 4 and Ki67 in MF.
Methods
1.27 cases diagnosed by clinic and pathology as granuloma fungoides in the last ten years in the department of Dermatology of QiLu Hospital were collected. As normal control,5 normal skin specimens obtained from clinic Operating Room and Plastic Surgery,were fixed by formaldehyde and embedded by paraffin.As inflammation control,5 lichen planus were obtained from Pathology Room of Dermatology.
2.The expression of PDCD4 and Ki67 in epidermis and dermis was detected by immunohistochemistry technique.
3.By using JMTJFX concise statistical analysis software 10.34,the expression of protein PDCD4 and Ki67 in epidermis and dermis was tested by rank-sum test of multisample by unitizing engineered or analysis of variance;The relevance of the two protein was analysed by Spearman'S rank correlation,the statistically significant difference is P＜0.05.
Results
1.Location and intensity of PDCD4 in immunohistochemical stain
Normal control specimens were all strong positive,mostly with brownish palm color,and positive expression was located mainly in the nuclear.
In LP,the keratinocyte and lymphocyte in dermis were widespreadly positive with buffy almost in nuclear,intense distribution.
In erythema/plaque stage MF,slightly decreased positive cells with buffy or pallide-flavens in epidermis were observed and the positive expression was located in both nuclear and kytoplasm;obviously decreased positive cells in dermis with buffy or pallide-flavens were observed in both nuclear and kytoplasm.
In tumor stage MF,significantly decreased positive cells in epidermis and dermis stained mostly in kytoplasm with diffused distribution,partly absent in dermis.
2.Comparison of positive expression intensity among all groups(PDCD4).
In epidermis,from normal control、erythema/plaque stage MF to tumor stage MF,or From LP、erythema/plaque stage MF to tumor stage MF,the expression of PDCD4 weakened gradiently.There was no significant difference in the number of PDCD4~+ cells between patch/plaque stage MF and normal control or LP(P＞0.05), and there was significant difference among the rest groups(P＜0.05).
In dermis,from normal control、erythema/plaque stage MF to tumor stage MF,or From LP、erythema/plaque stage MF to tumor stage MF,the expression of PDCD4 weakened gradiently.There was no significant difference in the number of PDCD4~+ cells between patch/plaque stage MF and LP(P＞0.05),and there was significant difference in the rest groups comparison(P＜0.05).
3.Location and intensity of Ki67:all in nuclear
Positive basal cell with buffy in normal control was partially observed;and negative in dermis.
In LP,the positive basal cells distributed discontinuously,the expression decreased where there were liquefaction of basal cells and increased in other place. Positive cells with buffy in dermis were more and intense.
In erythema/plaque stage MF,positive cells with huffy decreased in basal layer and slightly increased in epidermis,while scattered in dermis.
In tumor stage MF,positive cells with brown in epidermis scarcely increased while were intense in dermis,and cells obformed with karyomegaly anachromasis.
4.Comparison of positive expression intensity among all groups(Ki67)
In epidermis,there were no significant differences among all groups.
In dermis,from normal control、erythema/plaque stage MF to tumor stage MF, the expression of Ki67 gradiently increased and there were significant difference among group comparison(P＜0.05).There were no significant difference between LP and erythema/plaque stage MF or LP and tumor stage MF(P＞0.05),while there was in latter two group comparison(P＜0.05).
5.correlation analysis between PDCD4 and Ki67:
There was on correlation of PDCD4 and Ki67 either in erythema/plaque stage MF or in tumor stage MF(P＞0.05).
Conclusion
1.The expression of PDCD4 in epidermis keratinocyte,with the progression of MF,obviously down regulated even absent,indicates that keratinocyte may play an important role in the pathopoiesis and progression of MF.But the detail role needs further investigation.
2.The expression of PDCD4 in infiltrating lymphocyte of dermis,with the progression of MF,obviously down regulated even absent,indicates that PDCD4 intimately correlates with the pathopoiesis and progression of MF.It may contribute to inhibit excessly proliferation of lymphocyte by up-regulating the expression of PDCD4,and PDCD4 is expected to be a new target for treating CTCL.
3.The expression of Ki67 in normal control、erythema/plaque stage MF and tumor stage MF rises up gradually,which suggests that Ki67 antigen relates to the proliferation of lymphocyte in dermis,but there is no significant difference with LP.So we consider that Ki67 alone can't be the criteria to judge if cells proliferate malignantly.
4.No correlationship was observed between the expression of PDCD4 and Ki67, which suggests that apoptosis disturbance led by PDCD4 does not directly affect cells proliferation associated with Ki67.
蕈样肉芽肿(Mycosis Fungoides,MF)是原发于皮肤的亲表皮性皮肤T细胞淋巴瘤(cutaneous T cell lymphoma,CTCL),系一种最常见的低度恶性皮肤非霍奇金淋巴瘤。其早期局限于皮肤,随着病情的缓慢发展,晚期可侵犯淋巴结及内脏系统。MF的发病机制目前仍不清楚,讫今无满意的治疗方法。免疫学异常与其发病密切相关,表现为患者皮损中树突状细胞分布和功能异常,T细胞凋亡障碍,Fas表达下降和FasL表达增加,趋化因子及其受体、IL-4、IL-15、CTLA-4、HECA-452等免疫分子异常表达。其中T细胞的凋亡障碍导致肿瘤细胞的凋亡减少,从而促进MF的发展。
亲表皮现象是MF组织病理学的特征之一,这提示表皮细胞与淋巴细胞的相互作用可能在MF的发病中发挥一定作用。角质形成细胞(keratinocyte,KC)是人体表皮中的主要细胞,具有一定的抗原递呈作用,主动参与皮损中T细胞的再活化。同时其分泌的细胞因子在皮肤免疫系统中也发挥重要作用,MF时角质形成细胞中某些免疫分子的表达存在着显著不同,如IL-15蛋白的高度表达是皮肤T细胞淋巴瘤的一个特征。
PDCD4是一种抑癌基因,PDCD4蛋白是细胞凋亡所需要的新生的大分子复合物之一。其通过抑制肿瘤细胞的转录和翻译过程中起始复合物的形成抑制肿瘤细胞的生长。多种肿瘤细胞中PDCD4蛋白表达降低甚至缺失,并且随着肿瘤恶性程度的递增以及患者生存时间的减少,PDCD4的表达发生丢失情况也不断加重,证明PDCD4参与了多种肿瘤的发生和发展,在抑制肿瘤的形成中发挥了重要作用。目前已有PDCD4缺陷鼠自然发生淋巴瘤并且寿命显著缩短的报道,而且大多数肿瘤来源于B细胞,并不断转移到肝和肾。证明PDCD4在网状内皮系统肿瘤中也发挥了一定作用。关于皮肤T细胞淋巴瘤中该因子的表达及其影响的研究少见报道,表皮细胞在MF发病中的作用研究也较少。
Ki67抗原简称Ki67,是一种细胞核抗原,仅在增殖细胞核中表达,其单克隆抗体能标记G_1后期、S期、G_2期和M期细胞核,而G_0期和G_1早期细胞核不被标记。Ki67是目前应用最广泛的增殖细胞指标之一,是较为敏感的细胞增生分化指标。Ki67的测定是评估人类各种组织增殖组分可靠且简单的方法。
为此我们检测了PDCD4和Ki67蛋白在不同期蕈样肉芽肿的表皮及真皮中的表达,以正常皮肤为正常对照,以扁平苔藓为炎症对照,探讨PDCD4在MF发病中的作用,进而初步了解角质形成细胞在MF发病及病情进展中的作用。
目的:
检测并比较程序性细胞凋亡因子(PDCD4)、Ki67蛋白在正常皮肤、蕈样肉芽肿(MF)及扁平苔藓皮损中的表达,探讨程序性细胞凋亡因子在正常皮肤组织、炎症性皮肤病、不同期蕈样肉芽肿中的表达差异及临床意义,并比较两蛋白的相关性。
材料和方法:
1.收集齐鲁医院皮肤科近10年保存的经临床及病理确诊的27例MF完整蜡块,其中红斑/斑块期MF21例,肿瘤期MF6例;取门诊手术室及整形美容外科切除正常皮肤5例进行甲醛固定与石蜡包埋,作为正常对照组;另取皮肤科病理室保存的扁平苔藓石蜡标本5例,作为炎症对照组。
2.采用免疫组化方法检测并比较PDCD4及Ki67在不同期MF、LP及正常对照组中的表达情况。
3.应用JMT JFX简明统计分析软件10.34进行处理,统计方法采用成组设计多样本比较的秩和检验或方差分析;两蛋白的相关性用Spearman'S等级相关检验进行分析,P＜0.05为差异有统计学意义。
结果:
1.PDCD4在各组皮损中免疫组化染色位置及着色强度结果:
·5例正常对照组的表皮细胞和真皮浸润的淋巴细胞中PDCD4染色均为强阳性,多数为棕褐色,细胞核着色;
·5例扁平苔藓炎症对照组的表皮细胞和真皮浸润的淋巴细胞呈弥漫阳性,棕黄色,分布较密集,胞核染色;
·21例红斑/斑块期MF的表皮阳性细胞数量较正常对照组和扁平苔藓组略减少,胞核、胞浆均有阳性染色,为棕黄色或棕褐色;真皮中阳性细胞较前正常对照组和扁平苔藓组明显减少,胞核、胞浆染色,为棕黄色或淡黄色;
·6例肿瘤期MF表皮及真皮中阳性细胞均明显减少,散在分布,胞核或胞浆染色,部分真皮中PDCD4表达缺失。
·移入表皮的淋巴细胞不染色,真皮浅层距离表皮较近的淋巴细胞染色较淡或不染色。
2.各组PDCD4表达阳性等级的比较结果:
(1)表皮中:
①正常对照组、红斑/斑块期MF组到肿瘤期MF组,PDCD4表达从强阳性到阴性,呈梯度式减弱。红斑/斑块期MF组与正常对照组比较,差异无统计学意义(P＞0.05),其余各组比较,差异有统计学意义(P＜0.05);
②扁平苔藓组、红斑/斑块期MF组到肿瘤期MF组,PDCD4表达从强阳性到阴性,呈梯度式减弱。其中,红斑/斑块期MF组与扁平苔藓组比较,差异无统计学意义(P＞0.05),肿瘤期MF组与扁平苔藓组比较,差异有统计学意义(P＜0.05)。
(2)真皮中:
①正常对照组、红斑/斑块期MF组到肿瘤期MF组,PDCD4表达从强阳性到阴性,呈梯度式减弱。各组间差异均有统计学意义(P＜0.05);
②扁平苔藓组、红斑/斑块期MF组到肿瘤期MF组,PDCD4表达从强阳性到阴性,呈梯度式减弱。其中,红斑/斑块期MF组与扁平苔藓组相比较,差异无统计学意义(P＞0.05),肿瘤期MF组与扁平苔藓组比较差异有统计学意义(P＜0.05)。
3.Ki67蛋白在各组皮损中免疫组化染色位置及着色强度:均为细胞核染色
·5例正常对照组皮肤部分基底细胞阳性表达,棕黄色;真皮中阴性表达;
·5例扁平苔藓组表皮中基底层阳性细胞不连续性分布,基底细胞液化变性处表达减少,其余部分表达稍增多,均以基底层及其上细胞为主;真皮中阳性细胞较多,呈棕褐色或棕黄色,分布密集;
·红斑/斑块期MF组基底层细胞阳性减少,表皮内稍增多,棕黄色;真皮中阳性细胞分布稀疏,棕黄色;
·肿瘤期MF表皮阳性细胞增多不明显,棕褐色;真皮中阳性细胞分布较密集,细胞核大、异型者染色深。
4.各组Ki67表达的阳性细胞数量比较结果:
(1)表皮中:各组比较差异均无统计学意义;
(2)真皮中:
①正常对照组、红斑/斑块期MF组到肿瘤期MF组,Ki67的表达从阴性至强阳性,呈梯度式增强。各组间比较差异均有统计学意义(P＜0.05);
②扁平苔藓组分别与红斑/斑块期MF组和肿瘤期MF组比较差异均无统计学意义(P＞0.05),
5.PDCD4蛋白和Ki67蛋白的相关性分析:红斑/斑块期MF表皮中及真皮中PDCD4蛋白与Ki67蛋白的表达均无相关性(P＞0.05);肿瘤期MF表皮及真皮中PDCD4蛋白与Ki67蛋白的表达均无相关性(P＞0.05)。
结论:
1、随着MF病期的进展,表皮角质形成细胞PDCD4的表达明显下调甚至缺如,提示角质形成细胞在MF的发病及病程进展中可能发挥了重要作用,具体作用尚需进一步研究。
2、真皮中浸润淋巴细胞随着MF病期进展,PDCD4的表达明显下调甚至缺如,提示PDCD4与皮肤淋巴瘤MF的发生及病程进展密切相关,上调PDCD4的表达可能有助于抑制淋巴细胞的过度增殖,PDCD4有望成为皮肤T细胞淋巴瘤治疗的新靶点
3、Ki67在正常皮肤、红斑/斑块期MF及肿瘤期MF真皮中的表达梯度上升,表明Ki67抗原与真皮淋巴细胞的增殖有关,但与扁平苔藓组相比差异并无显著性,提示单一Ki67抗原并不能作为判断细胞恶性增殖的指标。
4、本实验的相关性研究并未发现各期MF皮损中PDCD4的表达与Ki67存在明显的相关性,提示与PDCD4相关的凋亡障碍与细胞的增殖不一定有直接联系。
Objective
To explore the expression of the Programmed Cell Death 4 and Ki67 antigen in the skin infiltrates of normal skin,skin lesions with mycosis fungoide (MF) in different stages and lichen planus(LP);And to explore the significance of the human programmed cell death 4 and Ki67 in MF.
Methods
1.27 cases diagnosed by clinic and pathology as granuloma fungoides in the last ten years in the department of Dermatology of QiLu Hospital were collected. As normal control,5 normal skin specimens obtained from clinic Operating Room and Plastic Surgery,were fixed by formaldehyde and embedded by paraffin.As inflammation control,5 lichen planus were obtained from Pathology Room of Dermatology.
2.The expression of PDCD4 and Ki67 in epidermis and dermis was detected by immunohistochemistry technique.
3.By using JMTJFX concise statistical analysis software 10.34,the expression of protein PDCD4 and Ki67 in epidermis and dermis was tested by rank-sum test of multisample by unitizing engineered or analysis of variance;The relevance of the two protein was analysed by Spearman'S rank correlation,the statistically significant difference is P＜0.05.
Results
1.Location and intensity of PDCD4 in immunohistochemical stain
Normal control specimens were all strong positive,mostly with brownish palm color,and positive expression was located mainly in the nuclear.
In LP,the keratinocyte and lymphocyte in dermis were widespreadly positive with buffy almost in nuclear,intense distribution.
In erythema/plaque stage MF,slightly decreased positive cells with buffy or pallide-flavens in epidermis were observed and the positive expression was located in both nuclear and kytoplasm;obviously decreased positive cells in dermis with buffy or pallide-flavens were observed in both nuclear and kytoplasm.
In tumor stage MF,significantly decreased positive cells in epidermis and dermis stained mostly in kytoplasm with diffused distribution,partly absent in dermis.
2.Comparison of positive expression intensity among all groups(PDCD4).
In epidermis,from normal control、erythema/plaque stage MF to tumor stage MF,or From LP、erythema/plaque stage MF to tumor stage MF,the expression of PDCD4 weakened gradiently.There was no significant difference in the number of PDCD4~+ cells between patch/plaque stage MF and normal control or LP(P＞0.05), and there was significant difference among the rest groups(P＜0.05).
In dermis,from normal control、erythema/plaque stage MF to tumor stage MF,or From LP、erythema/plaque stage MF to tumor stage MF,the expression of PDCD4 weakened gradiently.There was no significant difference in the number of PDCD4~+ cells between patch/plaque stage MF and LP(P＞0.05),and there was significant difference in the rest groups comparison(P＜0.05).
3.Location and intensity of Ki67:all in nuclear
Positive basal cell with buffy in normal control was partially observed;and negative in dermis.
In LP,the positive basal cells distributed discontinuously,the expression decreased where there were liquefaction of basal cells and increased in other place. Positive cells with buffy in dermis were more and intense.
In erythema/plaque stage MF,positive cells with huffy decreased in basal layer and slightly increased in epidermis,while scattered in dermis.
In tumor stage MF,positive cells with brown in epidermis scarcely increased while were intense in dermis,and cells obformed with karyomegaly anachromasis.
4.Comparison of positive expression intensity among all groups(Ki67)
In epidermis,there were no significant differences among all groups.
In dermis,from normal control、erythema/plaque stage MF to tumor stage MF, the expression of Ki67 gradiently increased and there were significant difference among group comparison(P＜0.05).There were no significant difference between LP and erythema/plaque stage MF or LP and tumor stage MF(P＞0.05),while there was in latter two group comparison(P＜0.05).
5.correlation analysis between PDCD4 and Ki67:
There was on correlation of PDCD4 and Ki67 either in erythema/plaque stage MF or in tumor stage MF(P＞0.05).
Conclusion
1.The expression of PDCD4 in epidermis keratinocyte,with the progression of MF,obviously down regulated even absent,indicates that keratinocyte may play an important role in the pathopoiesis and progression of MF.But the detail role needs further investigation.
2.The expression of PDCD4 in infiltrating lymphocyte of dermis,with the progression of MF,obviously down regulated even absent,indicates that PDCD4 intimately correlates with the pathopoiesis and progression of MF.It may contribute to inhibit excessly proliferation of lymphocyte by up-regulating the expression of PDCD4,and PDCD4 is expected to be a new target for treating CTCL.
3.The expression of Ki67 in normal control、erythema/plaque stage MF and tumor stage MF rises up gradually,which suggests that Ki67 antigen relates to the proliferation of lymphocyte in dermis,but there is no significant difference with LP.So we consider that Ki67 alone can't be the criteria to judge if cells proliferate malignantly.
4.No correlationship was observed between the expression of PDCD4 and Ki67, which suggests that apoptosis disturbance led by PDCD4 does not directly affect cells proliferation associated with Ki67.
引文
[1]Shibahara K,Asano M,Ishida Y,Aoki T,Koike T,Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death.Gene.1995,166:297-301.
[2]GokeA,GokeR,KnolhA,eta.DUG is a novel homologue of translation initiation factor 4G that binds elF4A[J].Biochem Biophys Res Conrmun 2002,297(1):78-82.
[3]Onishi Y,Hashimoto S,Kizaki H.Cloning of the TIS gene suppressed by topoisomerase inhibitors.Gene.1998,215:453-459.
[4]Hsin-Sheng Yang,Aaron P Jansen,Rajalakshmi Nair,A novel transformation suppressor,Pdcd4,inhibits AP-1 transactivation but not NF-kB or ODC transactivation.Oncogene(2001) 20,669-676.
[5]Jan sen A P,Camalier C E,Stark C,et al.Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drag sensitivity[J].Molecular Cancer Therapeutics,2004,3(2):103-110.
[6]Gao F,Wang X,Zhu F et al.PDCD4 gene silenching in gliomas is associated with 5'CpG island methylation and unfavorable prognosis[J].Journal of Cellular and Molecular Medicine,2008,13.
[7]Hilliard A,Hilliard B,Zheng SJ,et al.Translational Regulation of Autoimmune Inflammation and Lymphoma Genesis by Programmed Cell Death 4[J].The Journal of Immunology,2006,177(11):8095-8102.
[8]张思平,朱一元.蕈样肉芽肿的发病机制及治疗进展.国际皮肤性病学杂志2006:32(1):6-9.
[9]Mao X,Orchard G,Lillington DM,et al.Amplification and overexpression of JUNB is associated with Drimary cutan eous T.cell lymphomas Blood.2003.101:1513-1519.
[10]Navas IC,Algara P,Mateo M,et al.p16(INK4a)is selectively silenced in the tumoral progression of mycosis fungoides.Lab Invest,2002.82:123-132.
[11]Garatti SA,Rescetti E,Trecca D,et al.Bcl-1,bcl-2,p53,c-myc,and lyt-10analysis in cutaneous lymphomas.Recent Results Can.cer Res.1995.139: 249-261.
[12] Rose DS. Maddox PH. Brown DC. Which proliferation markers for routine imrnunohistology? A comparison of five antibodies[J] . J Clin Pathol,1994,47(11): 1010-1014.
[13] Soejima H, Miyoshi 0 ,Yoshinaga H, et al. Assignment of the programmed cell death 4 gene (PDCD4) to human chromosome band 10q24 by in situ hybridization. Cytogenet. 1999, 87(1-2):113-114.
[14] Goke A, Goke R, Knolle A, et al. DUG is a novel homologue of translation initiation factor 4G that binds eIF4A[J] . Biochem Biophys Res Commun,2002,297(1):78-82.
[15]KangMJ, AhnHS, Lee JY, etal. UP-regulation of PDCD4 in senescent human diploid fibroblastsl[J]. Biochem Biophys Res Commun, 2002 ,293(1):617-621.
[16] Yoshinaga H, Matsuhashi S, Ahanek J, et al. Expression and identification of H731 gene product in HeLa cells.Cell Mol Bio,1997, 1: 121.
[17] Cmarik JL, Min H, Hegamyer G, et al. Differentially expressed protein PDCD4 inhibits tumor promoter-induced neoplastic transformation, Proc Natl Acad Sci USA.1999,96:14037-14042.
[18] Jansen AP, Gamalier CE, Colbum NH. Epidemal expression of the translation inhibilot programmed cell death 4 suppresses tumorigenesis[J].Cancer Res,2005, 65(14): 6034-6041.
[19] Rogers GW Jr, Komar AA, Merrick C. eIF4A:the godfather of the DEAD box helicases. Prog Nucleic Acids Res Mol Biol. 2002, 72:307-331.
[20] Aravind L, Koonin EV. Eukaryote-specific domains in translation initiation factors: implications for translation regulation and evolution of the translation system. Genome Res. 2000,10:1172-1184.
[21] Ponting CP. Novel eIF4G domain homologues linking mRNA translation with nonsense-mediated mRNA decay. Trends Biochem Sci. 2000,25:423-426.
[22] Goke A, Goke R, Knolle A , Trusheim H, Schmidt H, Wilmen A, Carmody R,Goke B, Chen YH. DUG is a novel homologue of translation initiation factor 4G that binds eIF4A. Biochem Biophys Res Commun. 2002 Sep 13;297(1):78-82.
[23] Zakowicz H, Yang HS, Stark C, Wlodawer A, Laronde-Leblanc N, Colburn NH.Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor PDCD4 and eIF4AII characterizes its interaction with transformation suppressor PDCD4 and eIF4GI. RNA. 2005 Mar;11(3):261-274.
[24] Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ,Sonenberg N, Colburn NH . The transformation suppressor PDCD4 is a novel eukaryotic translation initiation factor 4A binding protein thant inhinbts translation. Mol Cell Biol. 2003 Jan; 23(1):26-37.
[25] YangHS, Jansen AP, Nair R, et al. A noveltransformation suppressor,PDCD4,inhibits AP-1 transactivation but not NF-kappaB or ODC transactivati-on[J]. Oneogene, 2001, 20(6): 669-676.
[26] Yang HS, Knies JL, Stark C, Colburn NH. PDCD4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene. 2003,22(24):3712-3720.
[27] Palamarchuk A, Efanov A, Maximov V, et al. Akt phosphorylates and regulate Pded4 tumor suppressor protein[J]. CancerRes, 2005, 65(24): 11282-11286.
[28] Goke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B. Programmed cell death protein 4 suppresses CDK1/CDC2 via induction of p21(Wafl/Cipl). Am J Physiol Cell Physiol. 2004 Dec; 287(6):C1541-1546.[
[29] Bohm M, Sawicka K, Siebrasse JP, Brehmer-Fastnacht A, Peters R, Klempnauer KH. The transformation suppressor protein PDCD4 shuttles between nucleus and cytoplasm and binds RNA. Oncogene.2003,22(31):4905-4910.
[30] Matsuhashi S, Narisawa Y, Ozaki I,et al. Expression patterns of programmed cell death 4 protein in normal human skin and some representative skin lesions[J].Experimental Dermatology,2007,16(3): 179-184.
[31] Chen Y, Knosel T, Kristiansen G, et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol.2003,200(5):640-646.
[32]Ma G,Guo KJ,Zhang H,et al.Expression of programmed cell death 4 and its clinicopathological significance in human pancreatic cancer.Zhongguo Yi Xue Ke Xue Yuan Xue Bao.2005,Oct;;27(5):597-600.
[33]Gao F,Zhang P,Zhou C,et al.Frequent loss of PDCD4 expression in human glioma:possible role in the tumorigenesis of glioma.Oncol Rep.2007,17(1):123-128.
[34]马刚,刘江,张浩,等.程序性细胞死亡因子4在胃癌组织中的表达及临床病理学意义[J].中华肿瘤防治杂志,2006,7(13):481-483.
[35]马刚,张浩,董明,等.程序性细胞死亡因子4在大肠癌组织中表达的临床病理学意义及其与预后的关系中华普通外科杂志[J],2007,1(22)67-68.
[36]Kitagawa,N.,M.Goto,K.Kurozumi,et al.Epstein-Barr virus-encoded poly(A)RNA supports Burkitt's lymphoma growth through interleukin-10 induction.EMBO J.2000,19:6742-6750.
[37]Czameski,J.,Y.C.Lin,S.Chong,et al.Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma.Leukemia 2004,18:597-606.
[38]Cameron,M.J.,G.A.Arreaza,P.Zucker,et al.IL-4 prevents insulitis and insulindependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function.J.Immunol.1997,159:4686-4692.
[39]Bettelli,E.,M.P.Das,E.D.Howard,et al.IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice.J.Immunol.1998,161:3299-3306.
[40]Samoilova,E.B.,J.L.Horton,and Y.Chen.Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice:roles of interleukin-10 in disease progression and recovery.Cell.Immunol.1998.188:118-124.
[41]Willemze R,Jaffe ES,Burg G,et al.WHO-EORTC classification for cutaneous lymphomas[J].Blood,2005,105(10):3768-3785.
[42]赵辨.临床皮肤病学.第3版.南京:江苏科学技术出版社,2001.1210-1216.
[43]van Doom R,van Haselen CW,vail Voorst Vader PC,et al.Mycosis fungoides:disease evolution and prognosis of 309 Dutch patients[J].Arch Dermatol,2000,136(4):504-510.
[44]Zackheim H,Amin S,Kashani-Sabet M,et al.Prognosis in cuntaneous Tcell lymphoma by skin stage:long-term survival in 489 patients[J].J Am Acad Dermatol,1999,40(3):418-425.
[45]Kim YH,Liu HL,Mraz-Gemhard S,et al,Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome:clinical prognostic factors and risk for disease progression[J].Arch Dermatol,2003,139(7):857-866.
[46]Wain EM,Orchard GE,Whittaker SJ,et al.Outcome in 34 patients with juvenile-onset mycosis fungoides:a clinical,immunOphenOtypic,and molecular study[J].Cancer,2003,98(10):2282-2290.
[47]王向东,夏治华,沈宏,等.18例蕈样肉芽肿临床分析[J].中国中西医结合皮肤性病学杂志,2005,4(2).92-94.
[48]曹发龙,吴文育,翁孟武.蕈样肉芽肿20例临床分析[J].中国皮肤性病学杂志,2005,19(6):351-352.
[49]Ku Ls,Lo KK.Mycosis fungoides-a retrospective study of 40 cases in Hong Kong[J].Int J Dermatol,2005,44(3):215-220.
[50]Rook AH.Vowels BR,Jaworsky C,et al.The immunopathogenesis of cutaneous T-cell lymphoma.Abnormal cytokine production by Sezary T cells.Arch Dermato1.1993.129:486-489.
[51]宋丽新,赵玉铭,李波等,蕈样肉芽肿T细胞抗原受体γ基因重排的研究[J].中华皮肤科杂志,2002.35(1)56.
[52]冯爱平,Mathias Luftl,Ecka Licha,等.蕈样肉芽肿浸润性皮损中树突细胞表型特征的研究.中华皮肤科杂志2003;36:92-94.
[53]Luftl M,Feng A,Licha E,et al.Dendritic cells and apoptosis in mycosis fungoides.Br J Dermatol 2002;147:1171-1179.
[54]Ferenczi K,Fuhlbrigge RC,Pinkus J,et al.Increased CCR4 expression in cutaneous T cell lymphoma.J Invest Dermatol。2002,119:1405-1410.
[55]冯爱平,赵静,吴艳,等.蕈样肉芽肿皮损中增生性T细胞与树突细胞的研究[J].中华皮肤科杂志,2006,39(4):207-209.
[56]Zoi-Toli O,Vermeer MH,De Vries E,et al.Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma(CTCL):association between lack of Fas expression and aggressive types of CTC L.Br J Dermatol,2000,143:313-319.
[57]Kallinich T,Muche JM,Qin S,et al.Chemokine receptor expression on neoplastic and reactive T cells in the skin at diferent stages of mycosis fungoides.J Invest Dermatol 2003;121:1045-1052.
[58]Fujita Y,Abe R,Sasaki M,et al.Presence of circulating CCR10+ T cells and elevated serum CTACK/CCL127 in the early stage of mycosis fungoides.Clin Cancer Res 2006:12:2670-2675.
[59]Papadavid E,Economidou J,Psarra A,et al.,The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and and Sezary syndrome.Br J Dermatol 2003:148:709-718.
[60]Leroy S,Dubois S,Tenaud I,et al.Interleukin-15 expression in cutaneous T-cell lymphoma(mycosis fungoides and Sezary syndrome).Br J Dermatol 2001;144:1016-1023.
[61]Wong HK,Wilson AJ,Gibson HM,et al.Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides- cutaneous T cell lymphoma.J Invest Dermatol 2006;126:212-219.
[62]Trolio R,Lorenzo G,Bazbiero E,et al.Expression of HECA-452 in parapsoriasis and mycosis fungoides.Int J Immunopathol Pharmaco 2006:19:105-110.
[63]Hiroyuki M,Paul RB,Akira T,et al.Keratinoeyte2derived IL-7 serves as a growth factor for dendritic epidermal T cells in mice.J Immunol,1993,151(11):6012-6019.
[64]Sean D.Doherty.Xiao Ni et al.Abnormal expression of intedeukin-23 in mycosis fugoides/Sezary syndrome lesions.Arch Dermatol Res,2006,298:353-356.
[65]Kei-ichi Yamanaka,Raehael Clark,Rebecca Dowgiert et al.Expression of Interleukin-18 and Caspase-1 in Cutaneous T-Cell Lymphoma.Clin Cancer Res 2006;12(2):376-382.
[66]Papadavid E,Economidou J,Psarra A,et al.The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sezary syndrome.Br J Dermatol 2003:148:709-718.
[67]Leroy S,Dubois S,Tenaud I,et al.Interleukin-15 expression in cutaneous T-cell lymphoma(mycosis fungoides and Sezary syndrome).Br JDennatol 2001;144:1016-1023.
[68]M.Sokolowska-Wojdylo,J.Wenzel,E.Gaffal,et al.Circulating clonal CLA+ and CD4+ T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7.British Journal of Dermatology 2005,152,258-264.
[69]AH Sarris,T Esgleyes-Ribot,M Crow,et al.Cytokine loops involving interferon-gamma and IP-10,a cytokine chemotactic for CD4+ lymphocytes:an explanation for the epidermotropism of cutaneous T-cell lymphoma? Blood,1995 86(2):651-658.
[70]V.Jarrousse,G.Quereux,S.Maroues-Briand,et al.Toll-like receptors 2,4 and 9expression in cutaneous T-cell lymphoma(mycosis fungoides and Sezary syndrome).Eur J Dermatol 2006,16(6):636-41.
[71]Nieves-Alicea R,Colburn NH,Simeone AM,et al.Programmed Cell Death 4inhibits breast cancer cell invasion by increasing Tissue Inhibitor of Mtalloproteinases- 2 expression[J].Breast Cancer Res Treat,2009,(114) 2:203 - 209.
[72]郭英军,何春涤,赵玉铭等.蕈样肉芽肿与扁平苔藓、银屑病浸润细胞的免疫组化比较.中华皮肤科杂志,2006,39(10)577-580.
[73]Azzoni L,Zatsepina O,Abebe B,et al.Diferential transcriptional regulation of CD161 and a novel gene,197/15a,by IL- 2,IL-15,and IL-12 in NK and T cells[J].J Immunol,1998,161(7):3493-3500.
[74]McCormick D,Hall PA.The complexities of prolifemting cell nuclear antigen [J].Histopathology.1992;21:591-4.
[75]Rose DSC,Maddox PH,Brown DC,et al.Which proliferation markers for routine immunohistology? A comparison of five antibodies[J].J Clin Pathol,1994;47:1010-4.
[76]Gerdes J,Schwab U,Lemke H,et al.Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferationInt J Cancer.1983 Jan 15;31(1):13-20.
[77]Gerdes J,Li L,Schlueter C,et al.Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.Am J Pathol.1991 Apr;138(4):867-73
[78]Gerdes J,Lemke H,Baisch H,et al.Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67[J]I Imnlunl 1984 133:1710-5.
[79]黄雪珍,吴晖,王剑峰,等。P53和Ki67在非霍奇金淋巴瘤中的表达及临床意义[J].临床肿瘤学杂志,2007,12(2):100-102.
[80]Azzoni L,Zatsepina O,Abebe B,et al.Diferential transcriptional regulation of CD161 and a novel gene,197/15a,by IL- 2,IL-15,and IL-12 in NK and T cells[J].J Immunol,1998,161(7):3493-3500.
[2]GokeA,GokeR,KnolhA,eta.DUG is a novel homologue of translation initiation factor 4G that binds elF4A[J].Biochem Biophys Res Conrmun 2002,297(1):78-82.
[3]Onishi Y,Hashimoto S,Kizaki H.Cloning of the TIS gene suppressed by topoisomerase inhibitors.Gene.1998,215:453-459.
[4]Hsin-Sheng Yang,Aaron P Jansen,Rajalakshmi Nair,A novel transformation suppressor,Pdcd4,inhibits AP-1 transactivation but not NF-kB or ODC transactivation.Oncogene(2001) 20,669-676.
[5]Jan sen A P,Camalier C E,Stark C,et al.Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drag sensitivity[J].Molecular Cancer Therapeutics,2004,3(2):103-110.
[6]Gao F,Wang X,Zhu F et al.PDCD4 gene silenching in gliomas is associated with 5'CpG island methylation and unfavorable prognosis[J].Journal of Cellular and Molecular Medicine,2008,13.
[7]Hilliard A,Hilliard B,Zheng SJ,et al.Translational Regulation of Autoimmune Inflammation and Lymphoma Genesis by Programmed Cell Death 4[J].The Journal of Immunology,2006,177(11):8095-8102.
[8]张思平,朱一元.蕈样肉芽肿的发病机制及治疗进展.国际皮肤性病学杂志2006:32(1):6-9.
[9]Mao X,Orchard G,Lillington DM,et al.Amplification and overexpression of JUNB is associated with Drimary cutan eous T.cell lymphomas Blood.2003.101:1513-1519.
[10]Navas IC,Algara P,Mateo M,et al.p16(INK4a)is selectively silenced in the tumoral progression of mycosis fungoides.Lab Invest,2002.82:123-132.
[11]Garatti SA,Rescetti E,Trecca D,et al.Bcl-1,bcl-2,p53,c-myc,and lyt-10analysis in cutaneous lymphomas.Recent Results Can.cer Res.1995.139: 249-261.
[12] Rose DS. Maddox PH. Brown DC. Which proliferation markers for routine imrnunohistology? A comparison of five antibodies[J] . J Clin Pathol,1994,47(11): 1010-1014.
[13] Soejima H, Miyoshi 0 ,Yoshinaga H, et al. Assignment of the programmed cell death 4 gene (PDCD4) to human chromosome band 10q24 by in situ hybridization. Cytogenet. 1999, 87(1-2):113-114.
[14] Goke A, Goke R, Knolle A, et al. DUG is a novel homologue of translation initiation factor 4G that binds eIF4A[J] . Biochem Biophys Res Commun,2002,297(1):78-82.
[15]KangMJ, AhnHS, Lee JY, etal. UP-regulation of PDCD4 in senescent human diploid fibroblastsl[J]. Biochem Biophys Res Commun, 2002 ,293(1):617-621.
[16] Yoshinaga H, Matsuhashi S, Ahanek J, et al. Expression and identification of H731 gene product in HeLa cells.Cell Mol Bio,1997, 1: 121.
[17] Cmarik JL, Min H, Hegamyer G, et al. Differentially expressed protein PDCD4 inhibits tumor promoter-induced neoplastic transformation, Proc Natl Acad Sci USA.1999,96:14037-14042.
[18] Jansen AP, Gamalier CE, Colbum NH. Epidemal expression of the translation inhibilot programmed cell death 4 suppresses tumorigenesis[J].Cancer Res,2005, 65(14): 6034-6041.
[19] Rogers GW Jr, Komar AA, Merrick C. eIF4A:the godfather of the DEAD box helicases. Prog Nucleic Acids Res Mol Biol. 2002, 72:307-331.
[20] Aravind L, Koonin EV. Eukaryote-specific domains in translation initiation factors: implications for translation regulation and evolution of the translation system. Genome Res. 2000,10:1172-1184.
[21] Ponting CP. Novel eIF4G domain homologues linking mRNA translation with nonsense-mediated mRNA decay. Trends Biochem Sci. 2000,25:423-426.
[22] Goke A, Goke R, Knolle A , Trusheim H, Schmidt H, Wilmen A, Carmody R,Goke B, Chen YH. DUG is a novel homologue of translation initiation factor 4G that binds eIF4A. Biochem Biophys Res Commun. 2002 Sep 13;297(1):78-82.
[23] Zakowicz H, Yang HS, Stark C, Wlodawer A, Laronde-Leblanc N, Colburn NH.Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor PDCD4 and eIF4AII characterizes its interaction with transformation suppressor PDCD4 and eIF4GI. RNA. 2005 Mar;11(3):261-274.
[24] Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ,Sonenberg N, Colburn NH . The transformation suppressor PDCD4 is a novel eukaryotic translation initiation factor 4A binding protein thant inhinbts translation. Mol Cell Biol. 2003 Jan; 23(1):26-37.
[25] YangHS, Jansen AP, Nair R, et al. A noveltransformation suppressor,PDCD4,inhibits AP-1 transactivation but not NF-kappaB or ODC transactivati-on[J]. Oneogene, 2001, 20(6): 669-676.
[26] Yang HS, Knies JL, Stark C, Colburn NH. PDCD4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene. 2003,22(24):3712-3720.
[27] Palamarchuk A, Efanov A, Maximov V, et al. Akt phosphorylates and regulate Pded4 tumor suppressor protein[J]. CancerRes, 2005, 65(24): 11282-11286.
[28] Goke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B. Programmed cell death protein 4 suppresses CDK1/CDC2 via induction of p21(Wafl/Cipl). Am J Physiol Cell Physiol. 2004 Dec; 287(6):C1541-1546.[
[29] Bohm M, Sawicka K, Siebrasse JP, Brehmer-Fastnacht A, Peters R, Klempnauer KH. The transformation suppressor protein PDCD4 shuttles between nucleus and cytoplasm and binds RNA. Oncogene.2003,22(31):4905-4910.
[30] Matsuhashi S, Narisawa Y, Ozaki I,et al. Expression patterns of programmed cell death 4 protein in normal human skin and some representative skin lesions[J].Experimental Dermatology,2007,16(3): 179-184.
[31] Chen Y, Knosel T, Kristiansen G, et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol.2003,200(5):640-646.
[32]Ma G,Guo KJ,Zhang H,et al.Expression of programmed cell death 4 and its clinicopathological significance in human pancreatic cancer.Zhongguo Yi Xue Ke Xue Yuan Xue Bao.2005,Oct;;27(5):597-600.
[33]Gao F,Zhang P,Zhou C,et al.Frequent loss of PDCD4 expression in human glioma:possible role in the tumorigenesis of glioma.Oncol Rep.2007,17(1):123-128.
[34]马刚,刘江,张浩,等.程序性细胞死亡因子4在胃癌组织中的表达及临床病理学意义[J].中华肿瘤防治杂志,2006,7(13):481-483.
[35]马刚,张浩,董明,等.程序性细胞死亡因子4在大肠癌组织中表达的临床病理学意义及其与预后的关系中华普通外科杂志[J],2007,1(22)67-68.
[36]Kitagawa,N.,M.Goto,K.Kurozumi,et al.Epstein-Barr virus-encoded poly(A)RNA supports Burkitt's lymphoma growth through interleukin-10 induction.EMBO J.2000,19:6742-6750.
[37]Czameski,J.,Y.C.Lin,S.Chong,et al.Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma.Leukemia 2004,18:597-606.
[38]Cameron,M.J.,G.A.Arreaza,P.Zucker,et al.IL-4 prevents insulitis and insulindependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function.J.Immunol.1997,159:4686-4692.
[39]Bettelli,E.,M.P.Das,E.D.Howard,et al.IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice.J.Immunol.1998,161:3299-3306.
[40]Samoilova,E.B.,J.L.Horton,and Y.Chen.Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice:roles of interleukin-10 in disease progression and recovery.Cell.Immunol.1998.188:118-124.
[41]Willemze R,Jaffe ES,Burg G,et al.WHO-EORTC classification for cutaneous lymphomas[J].Blood,2005,105(10):3768-3785.
[42]赵辨.临床皮肤病学.第3版.南京:江苏科学技术出版社,2001.1210-1216.
[43]van Doom R,van Haselen CW,vail Voorst Vader PC,et al.Mycosis fungoides:disease evolution and prognosis of 309 Dutch patients[J].Arch Dermatol,2000,136(4):504-510.
[44]Zackheim H,Amin S,Kashani-Sabet M,et al.Prognosis in cuntaneous Tcell lymphoma by skin stage:long-term survival in 489 patients[J].J Am Acad Dermatol,1999,40(3):418-425.
[45]Kim YH,Liu HL,Mraz-Gemhard S,et al,Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome:clinical prognostic factors and risk for disease progression[J].Arch Dermatol,2003,139(7):857-866.
[46]Wain EM,Orchard GE,Whittaker SJ,et al.Outcome in 34 patients with juvenile-onset mycosis fungoides:a clinical,immunOphenOtypic,and molecular study[J].Cancer,2003,98(10):2282-2290.
[47]王向东,夏治华,沈宏,等.18例蕈样肉芽肿临床分析[J].中国中西医结合皮肤性病学杂志,2005,4(2).92-94.
[48]曹发龙,吴文育,翁孟武.蕈样肉芽肿20例临床分析[J].中国皮肤性病学杂志,2005,19(6):351-352.
[49]Ku Ls,Lo KK.Mycosis fungoides-a retrospective study of 40 cases in Hong Kong[J].Int J Dermatol,2005,44(3):215-220.
[50]Rook AH.Vowels BR,Jaworsky C,et al.The immunopathogenesis of cutaneous T-cell lymphoma.Abnormal cytokine production by Sezary T cells.Arch Dermato1.1993.129:486-489.
[51]宋丽新,赵玉铭,李波等,蕈样肉芽肿T细胞抗原受体γ基因重排的研究[J].中华皮肤科杂志,2002.35(1)56.
[52]冯爱平,Mathias Luftl,Ecka Licha,等.蕈样肉芽肿浸润性皮损中树突细胞表型特征的研究.中华皮肤科杂志2003;36:92-94.
[53]Luftl M,Feng A,Licha E,et al.Dendritic cells and apoptosis in mycosis fungoides.Br J Dermatol 2002;147:1171-1179.
[54]Ferenczi K,Fuhlbrigge RC,Pinkus J,et al.Increased CCR4 expression in cutaneous T cell lymphoma.J Invest Dermatol。2002,119:1405-1410.
[55]冯爱平,赵静,吴艳,等.蕈样肉芽肿皮损中增生性T细胞与树突细胞的研究[J].中华皮肤科杂志,2006,39(4):207-209.
[56]Zoi-Toli O,Vermeer MH,De Vries E,et al.Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma(CTCL):association between lack of Fas expression and aggressive types of CTC L.Br J Dermatol,2000,143:313-319.
[57]Kallinich T,Muche JM,Qin S,et al.Chemokine receptor expression on neoplastic and reactive T cells in the skin at diferent stages of mycosis fungoides.J Invest Dermatol 2003;121:1045-1052.
[58]Fujita Y,Abe R,Sasaki M,et al.Presence of circulating CCR10+ T cells and elevated serum CTACK/CCL127 in the early stage of mycosis fungoides.Clin Cancer Res 2006:12:2670-2675.
[59]Papadavid E,Economidou J,Psarra A,et al.,The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and and Sezary syndrome.Br J Dermatol 2003:148:709-718.
[60]Leroy S,Dubois S,Tenaud I,et al.Interleukin-15 expression in cutaneous T-cell lymphoma(mycosis fungoides and Sezary syndrome).Br J Dermatol 2001;144:1016-1023.
[61]Wong HK,Wilson AJ,Gibson HM,et al.Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides- cutaneous T cell lymphoma.J Invest Dermatol 2006;126:212-219.
[62]Trolio R,Lorenzo G,Bazbiero E,et al.Expression of HECA-452 in parapsoriasis and mycosis fungoides.Int J Immunopathol Pharmaco 2006:19:105-110.
[63]Hiroyuki M,Paul RB,Akira T,et al.Keratinoeyte2derived IL-7 serves as a growth factor for dendritic epidermal T cells in mice.J Immunol,1993,151(11):6012-6019.
[64]Sean D.Doherty.Xiao Ni et al.Abnormal expression of intedeukin-23 in mycosis fugoides/Sezary syndrome lesions.Arch Dermatol Res,2006,298:353-356.
[65]Kei-ichi Yamanaka,Raehael Clark,Rebecca Dowgiert et al.Expression of Interleukin-18 and Caspase-1 in Cutaneous T-Cell Lymphoma.Clin Cancer Res 2006;12(2):376-382.
[66]Papadavid E,Economidou J,Psarra A,et al.The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sezary syndrome.Br J Dermatol 2003:148:709-718.
[67]Leroy S,Dubois S,Tenaud I,et al.Interleukin-15 expression in cutaneous T-cell lymphoma(mycosis fungoides and Sezary syndrome).Br JDennatol 2001;144:1016-1023.
[68]M.Sokolowska-Wojdylo,J.Wenzel,E.Gaffal,et al.Circulating clonal CLA+ and CD4+ T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7.British Journal of Dermatology 2005,152,258-264.
[69]AH Sarris,T Esgleyes-Ribot,M Crow,et al.Cytokine loops involving interferon-gamma and IP-10,a cytokine chemotactic for CD4+ lymphocytes:an explanation for the epidermotropism of cutaneous T-cell lymphoma? Blood,1995 86(2):651-658.
[70]V.Jarrousse,G.Quereux,S.Maroues-Briand,et al.Toll-like receptors 2,4 and 9expression in cutaneous T-cell lymphoma(mycosis fungoides and Sezary syndrome).Eur J Dermatol 2006,16(6):636-41.
[71]Nieves-Alicea R,Colburn NH,Simeone AM,et al.Programmed Cell Death 4inhibits breast cancer cell invasion by increasing Tissue Inhibitor of Mtalloproteinases- 2 expression[J].Breast Cancer Res Treat,2009,(114) 2:203 - 209.
[72]郭英军,何春涤,赵玉铭等.蕈样肉芽肿与扁平苔藓、银屑病浸润细胞的免疫组化比较.中华皮肤科杂志,2006,39(10)577-580.
[73]Azzoni L,Zatsepina O,Abebe B,et al.Diferential transcriptional regulation of CD161 and a novel gene,197/15a,by IL- 2,IL-15,and IL-12 in NK and T cells[J].J Immunol,1998,161(7):3493-3500.
[74]McCormick D,Hall PA.The complexities of prolifemting cell nuclear antigen [J].Histopathology.1992;21:591-4.
[75]Rose DSC,Maddox PH,Brown DC,et al.Which proliferation markers for routine immunohistology? A comparison of five antibodies[J].J Clin Pathol,1994;47:1010-4.
[76]Gerdes J,Schwab U,Lemke H,et al.Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferationInt J Cancer.1983 Jan 15;31(1):13-20.
[77]Gerdes J,Li L,Schlueter C,et al.Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.Am J Pathol.1991 Apr;138(4):867-73
[78]Gerdes J,Lemke H,Baisch H,et al.Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67[J]I Imnlunl 1984 133:1710-5.
[79]黄雪珍,吴晖,王剑峰,等。P53和Ki67在非霍奇金淋巴瘤中的表达及临床意义[J].临床肿瘤学杂志,2007,12(2):100-102.
[80]Azzoni L,Zatsepina O,Abebe B,et al.Diferential transcriptional regulation of CD161 and a novel gene,197/15a,by IL- 2,IL-15,and IL-12 in NK and T cells[J].J Immunol,1998,161(7):3493-3500.